CSIMarket


Allakos Inc   (ALLK)
Other Ticker:  
 


 

Allakos Inc

ALLK's Financial Statements and Analysis



Allakos Inc narrowed third quarter of 2023 net loss per share of $-0.52 compare to net loss per share of $-0.53 recorded in the same quarter a year ago a decrease compare to $-0.41 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.52 $  0 Mill
$+0.01     Unch.    



Allakos Inc 's Revenue fell by 0 % in third quarter of 2023 (Sep 30 2023) year on year, to $0 million and declined by sequentially.


Allakos Inc is

More on ALLK's Income Statement



Allakos Inc in the third quarter of 2023 recorded net loss of $-45.626 million, an increase from net loss of $-30.837 million in III. Quarter a year ago.

Sequentially net loss advanced

More on ALLK's Growth

Allakos Inc Inventories
ALLK's Cash flow In the third quarter of 2023 company's net cash flow was $3 million, capital expenditures grew by -2.343-95.43%, to $0 millions compare to same quarter a year ago

More on ALLK's Cash flow Statement


Allakos Inc does not pay out common stock dividend.

In trailing twelve-month period Allakos Inc payed $ -1.60 cash per share, on a free-cash flow basis .

Book value fell by -13.78 % sequentially to $2.54 per share, -21.34% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 2.54 per share from $ 2.94.

Company issued 0.47 million shares or 0.54 % in Sep 30 2023.


More on ALLK's Dividends

 Market Capitalization (Millions) 124
 Shares Outstanding (Millions) 87
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -166
 Cash Flow (TTM) (Millions $) -135
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 149




Allakos Inc does not pay out common stock dividend.

In trailing twelve-month period Allakos Inc had negative $ -1.60 cash flow per share, on a free-cash flow basis .

Book value fell by -13.78 % sequentially to $2.54 per share, -21.34% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 2.54 per share from $ 2.94.

Company issued 0.47 million shares or 0.54 % in Sep 30 2023.


More on ALLK's Balance Sheets

 Market Capitalization (Millions) 124
 Shares Outstanding (Millions) 87
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -166
 Cash Flow (TTM) (Millions $) -135
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 149
   


  News about Allakos Inc Earnings

Major Pharmaceutical Preparations Company, Allakos Inc., Reports Significant Reduction in Financial Performance during the Third Quarter of 2023



As the reporting season for July to September 30, 2023 continues, several businesses from various industries have released their financial numbers. One notable industry affected by recent financial challenges is Major Pharmaceutical Preparations, which includes Allakos Inc. Their recent report of an operating deficit of $-48.21 million in the fiscal third quarter of 2023 has raised concerns among investors. While the revenue figures are yet to be disclosed, comparing previous performances can provide valuable insights into the company's financial position and future prospects.
Financial Challenges and Revenue Generation:
Allakos Inc, an ascending player in the pharmaceutical industry, is cu...

Allakos Inc, a Major Pharmaceutical Preparations industry player, reports significant improvement in Q2 2023 with operating deficit reducing to $-49.117 million, showing economic enhancement despite challenging sector standards

Allakos Inc, a lesser-known player in the Major Pharmaceutical Preparations sector, recently reported its earnings for the second quarter of 2023. The company disclosed an operating deficit of $-37.817 million, which may seem concerning at first glance. However, when compared to the operating deficit of $-49.117 million in the same period last year, there is a notable improvement.
This positive trend is generating optimism among analysts who see it as a promising revelation, especially considering the challenging standards faced by companies in this sector. During the financial second quarter of 2023, Allakos Inc managed to operate more economically, resulting in a reduction of diminishing returns to $-3...

ALLK Announces Improved First Quarter 2023 Performance Amidst Challenging Market

Allakos Inc. is a leading company in the pharmaceutical preparations industry. The San Carlos-based firm specializes in the development of therapeutic antibodies that address serious medical conditions associated with the immune system. Their efforts are geared towards helping patients with unmet medical needs in the treatment of diseases including urticaria, eosinophilic gastritis and other inflammatory and allergic conditions.
The earnings season for the period of January to March 2023 has resumed and the results for Allakos Inc. have been recently disclosed. The company has announced an operating deficit of $-45.046 million for the fiscal year ending March 31, 2023. However, there is cause for optimis...


Date modified: 2023-11-14T21:56:42+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com